Prevalence and Clinical Implications of Concurrent CBD Stones

Epidemiological Data

The general gallstone population has a prevalence of concurrent CBD stones of 10-20% 1, 3
Patients with acute calculous cholecystitis have a lower incidence of concurrent CBD stones, ranging from 5-15% 1, 2

The American College of Surgeons and other surgical guidelines suggest that routine invasive testing for all gallstone patients is not warranted due to the relatively modest prevalence of 10-20%, but selective evaluation based on risk stratification is essential 1, 2
Most CBD stones are secondary, originating in the gallbladder and migrating into the bile duct rather than forming de novo, as noted by the World Journal of Emergency Surgery 4
Even in the presence of gallstones, the majority (80-90%) of patients do not have concurrent CBD stones, making risk stratification critical to avoid unnecessary procedures 1, 2
Untreated CBD stones carry significant morbidity, with 25.3% of patients experiencing unfavorable outcomes including pancreatitis, cholangitis, or bile duct obstruction 4

Elevated liver function tests alone are insufficient for diagnosis, as 15-50% of patients with acute cholecystitis without CBD stones have elevated LFTs due to inflammation rather than obstruction, according to the World Journal of Emergency Surgery 1, 2
Normal liver function tests have a negative predictive value of 97%, but abnormal liver function tests have only a 15% positive predictive value 1, 2